Chang MA

Language: Spanish
References: 14
Page: 41-44
PDF size: 44.10 Kb.

Text Extraction

No abstract.

REFERENCES

1. Ciurea SO, Bayraktar UD. "No donor"? Consider a haploidentical transplant. Blood reviews. 2015;29(2):63-70.

2. Bashey A, Solomon SR. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014;49(8):999-1008.

3. Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014;20(10):1573-9.

4. McCurdy SR, Kasamon YL, Kanakry CG, Bolanos-Meade J, Tsai HL, Showel MM, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017;102(2):391-400.

5. Chang YJ, Luznik L, Fuchs EJ, Huang XJ. How do we choose the best donor for Tcell- replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016;9:35.

6. Solomon SR, Aubrey MT, Zhang X, Piluso A, Freed BM, Brown S, et al. Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables. Biol Blood Marrow Transplant. 2018;24(4):789-98.

7. McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, et al. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood advances. 2018;2(3):299-307.

8. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC)2011.

9. Wiebe C, Nickerson P. Human leukocyte antigen mismatch and precision medicine in transplantation. Curr Opin Organ Transplant. 2018;23(4):500-5.

10. Sirota M, Sarwal MM. Transplantomics: Toward Precision Medicine in Transplantation Research. Transplantation. 2017;101(8):1777-82.

11. Macías Abraham C. Histocompatibilidad: pasado, presente y futuro. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2015 [citado 14 ago 2018]; 31(1):[53-8 pp.]. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892015000100006&lng=es&nrm=iso .

12. Bencomo Hernández A. Compatibilidad de epítopes HLA para el trasplante. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2017[citado 14 ago 2018]; 33(3). Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892017000300001&lng=es&nrm=iso&tlng=es .

13. Duquesnoy R, Spellman S, Haagenson M, Wang T, Horowitz MM, Oudshoorn M. HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors. Biol Blood Marrow Transplant. 2008;14(9):1064-71.

14. Costales Elizalde DT, Morera Barrios LM, González García N, Chang Monteagudo A, Marcell Rodríguez L, Ustariz García C, et al. Anticuerpos anti Citomegalovirus y anti virus de Epstein Barr en pacientes en espera de trasplante de Células Progenitoras Dematopoyéticas en Cuba. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2017[citado 14 ago 2018]; 33(2). Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 02892017000200011&lng=es&nrm=iso&tlng=es.